Notícias e Atividades da Genor Biopharma

Genor Biopharma pertence à H&H Group. H&H Group tem presença direta em 3 países.

H&H Group possui 5 subsidiárias incluindo Creo Media Group, Genor Biopharma e H&H Insurance Brokers.

Eles estão dentro:

• Serviços Financeiros17%
• Mídia17%
• Outro67%

Veja o organograma con seus 7 executivos principais

Biografias mais buscadas da Genor Biopharma

• Feng Guo, Chairman of the Board and Chief Executive Officer
• Dong Lyu, Non-Executive Director
• Qibin Liang, Chief Technology Officer

Criar um alerta
para seguir os movimentos de executivos da Genor Biopharma.

H&H Group possui 2.066 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Optum (Estados Unidos) e Siemens Healthineers (Alemanha).

Popular M&A news in Saúde

• CareSource adquiriu Commonwealth Care Alliance (publicado em 1 de maio de 2025).
• Nourish acaba de anunciar uma arrecadação de fundos de 70 milhões de dólares. (publicado em 25 de abril de 2025).
• Accolade and Accolade have announced they will merge  (publicado em 9 de abril de 2025)..

Outros contatos sugeridos na indústria do Saúde

• Paulo Junqueira Moll - Chief Executive Officer da Rede D'Or Sao Luiz
• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Bryan Roberts - Director da Included Health

Saiba mais sobre a indústria do Saúde

Últimos comunicados de imprensa de Genor Biopharma

• Genor Biopharma Co. Ltd | The research data of Lerociclib(GB491) was published on Nature Communications, Genor Biopharma’s highly selective oral CDK4/6 inhibitor again recognized at globe
• Genor Biopharma Co. Ltd | Genor Biopharma presents the safety and efficacy results of GB263T at 2024 ESMO
• Genor Biopharma Co. Ltd | Genor Biopharma Releases Its Interim Results for 2023
• Genor Biopharma Co. Ltd | Corporate News
• Genor Biopharma Co. Ltd | Genor Biopharma has entered into an exclusive global licensing agreement with TRC 2004, INC.
• Genor Biopharma Co. Ltd | Genor Biopharma Releases Its Annual Results for 2023
• Genor Biopharma Co. Ltd | National Medical Products Administration Accepts New Drug Application for GB491 (Lerociclib)
• Genor Biopharma Co. Ltd | Genor Biopharma presents the safety and efficacy results of GB261 at 2023 ASH
• Genor Biopharma Co. Ltd | Corporate News
• Genor Biopharma Co. Ltd | The latest updates of GB263T were published in Molecular Cancer Therapeutics
• View more press releases Close

Redes sociais sobre Genor Biopharma

• Genor Biopharma na Wikipedia, Google News e Yahoo Finance
• Genor Biopharma na LinkedIn, Twitter e YouTube